New Delhi – November 25, 2024 – Genpact (NYSE: G), a global professional services and solutions firm delivering outcomes that shape the future, today announced the extension of its partnership with Ferring Pharmaceuticals, a research-driven biopharmaceutical company that has operating subsidiaries in more than 50 countries and markets its medicines in over 100 countries. The renewed multi-year agreement will continue the transformation of Ferring’s finance, accounting, and procurement operations with advanced technologies, including AI.
“To drive growth in a complex and competitive environment, pharmaceutical companies need modern, scalable and efficient solutions,” said Sanjiv Tandon, Global Head of Life Sciences and Healthcare, Genpact. “Our ongoing partnership with Ferring Pharmaceuticals leverages our industry expertise and a shared vision to harness advanced technologies, setting a new standard for innovation and enabling Ferring to meet evolving demands with speed and accuracy.”
Under the agreement, Genpact will continue to streamline workflows, optimize resource allocation, and improve the accuracy and speed of financial transactions. In collaboration with technology partners like Xelix and Blackline, Genpact will automate key processes, such as invoice management and procurement workflows, while establishing robust data analytics capabilities for real-time financial insights. These enhancements aim to deliver significant operational savings and enable Ferring to adapt swiftly to evolving customer and patient needs.
“Our partnership with Genpact spans over 40 digital transformation projects, with a strong focus on AI applications,” said Dominic Moorhead, Chief Financial Officer, Ferring Pharmaceuticals. “By standardizing processes and leveraging advanced technologieslike AI, we’re enhancing accuracy, real-time insights, and overall efficiency to support our purpose of building families and helping people live better lives.”
This collaboration underscores Ferring Pharmaceuticals’ commitment to innovation, enabling the company to thrive and deliver its range of innovative treatments to change the lives of people and families around the world.
Comments are closed.